E
FTH

Ergoteles’s Faeth Therapeutics FTH Stock Holding History

Ergoteles’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-776
Closed -$23.3K – 1490
2023
Q1 		$23.3K Sell
776
-941
-55% -$27.9K ﹤0.01% 1154
2022
Q4 		$51.2K Sell
1,717
-2,781
-62% -$81.8K ﹤0.01% 1291
2022
Q3 		$139K Sell
4,498
-182
-4% -$7.15K ﹤0.01% 1296
2022
Q2 		$212K Buy
+4,680
New +$175K 0.01% 1293

Other funds holding FTH

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ergoteles's FTH Position: Q2 2023 in Review

Ergoteles sold out of Faeth Therapeutics (FTH) in Q2 2023, closing a stake of 776 shares — an estimated $23.3K sold.

Ergoteles first reported a position in FTH in Q2 2022 and held it in 4 quarters. The position peaked at $212K in Q2 2022. 24 funds tracked by Wall St. Rank hold FTH as of Q2 2023.

  • Ergoteles reported no remaining Faeth Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 776 Faeth Therapeutics shares in Q2 2023, an estimated $23.3K.
  • Ergoteles first reported a position in Faeth Therapeutics in Q2 2022 and held it in 4 quarters.
  • Ergoteles's Faeth Therapeutics position peaked at $212K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.